This is a recording of a live event hosted on 10/28/25.
The COVID-19 Vaccine and its administration are covered as preventive services under Medicare Part B’s Preventive Services benefits.
During this event, we:
– Provided background information about COVID-19 including symptoms,
testing, and treatment
– Reviewed different types of COVID-19 vaccines available for the 2025–2026
season
– Discussed Medicare Part B coverage criteria for COVID-19 Vaccine &
Administration
Resources:
MLN006559 Medicare Preventive Services – COVID-19 Vaccine & Administration
https://www.cms.gov/medicare/prevention/prevntiongeninfo/medicare-preventive-services/mps-quickreferencechart-1.html#COVID
Medicare COVID-19 Vaccine Shot Payment
https://www.cms.gov/medicare/payment/covid-19-vaccine-toolkit/medicare-covid-19-vaccine-shot-payment#Home
Medicare Billing for COVID-19 Vaccine Shot Administration
https://www.cms.gov/medicare/payment/covid-19-vaccine-toolkit/medicare-billing-covid-19-vaccine-shot-administration
Survey Link:
Your opinion matters! Please consider providing feedback by taking our survey:
https://cmsmacfedramp.gov1.qualtrics.com/jfe/form/SV_bCsIdQBnSfzDzq5?EventType=Video&Title=Encore%3A%20COVID-19%20Vaccine%20and%20Administration%20%28Clinical%29&Date=10%2F28%2F2025&Presenter=Jennifer%20Boniface
Chapters:
00:00 Introduction
03:37 Objective and Agenda
05:38 Background on COVID-19
23:08 COVID-19 Vaccines
30:00 Coverage
30:50 Additional Coverage Information
35:40 Documentation
37:05 Resources
38:31 Closing Remarks
Hello and welcome to our webinar on COVID 19 vaccine and administration. My name is Jennifer Bonifac and I am one of the nurse analysts with the provider outreach and education team. Today’s webinar will focus on the clinical aspects for the Medicare preventive service of COVID 19 vaccine and its administration. I have a few housekeeping items to go over with you before we start the webinar. You can find the link to the encore presentation of this webinar on our website’s training center page at www.wpsgha.com and it will be accessible for next 60 to 90 days. Additionally, the recording will be uploaded to our YouTube channel under the encore presentations playlist and both should be available within the next 15 business days. If you have any questions, please put those questions in the chat. We will answer questions as time permits. And should we be unable to answer a question during the webinar, we will create a follow-up document and send it to all attendees afterward. We really want your feedback. It helps us develop the education on topics that may be of interest to you. Consider taking our survey to let CMS know what you did like and what topics you’d like to learn more about. And Tom placed a link to the survey into the chat. There is also be an opportunity at the end to take the survey. Additionally, you can provide feedback by completing the survey or viewing the encore presentation. To access the survey, click on the circle with the eye in the upper right corner of the video. And a link of the to the survey can be found in the description video as well. I will be focusing on the clinical aspects of COVID 19 vaccine and administration during this webinar. For more information about the billing aspects of CO 19, please watch our encore presentation titled Encore preventive services influenza numacco and co vaccines and administration. And you can find the encore presentation of that webinar on our YouTube channel under the playlist encore presentations. And I’ve placed a link to the encore presentations playlist on the resources slide at the end of this presentation. So you can refer to that um link to get that um those webinars. This webinar presents the most up-to-date rules and regulations regarding COVID 19 vaccinations as of today. However, this information is subject to change. To stay current, please refer to the most recent updates published by the CDC and Advisory Committee on Immunization Practices as those take precedence over any content presented here. Also, please note that Medicare coverage guidelines are dependent on CMS implementation. On this next slide, we have our disclaimer. Medicare rules change often, so please make sure you’re looking at official CMS communications for the most up-to-date rules and regulations, and these do take precedence over anything presented today. And as a reminder, CMS prohibits recording of this presentation for profitm purposes. This presentation is being recorded by us and will be posted on the training center page of our website under encore presentations as well as on our YouTube channel under the playlist encore presentations. On this next slide, you’ll see several different acronyms used during this presentation. Many of them you already know, but if you find an acronym we discussed today that you’re unfamiliar with, please refer to the slide for guidance. On September 19th, 2025, the CDC’s Advisory Committee on Immunization Practices unanimously recommended the CO 19 vaccination decisions be made on individual decision-making for all individuals aged 6 months and older. The guidance emphasizes the importance on considering the risks and benefits of vaccination. It suggests that vaccination is most beneficial for individuals under 65 who are at a higher risk for CO 19 such as those with underlying medical conditions and lowest for those who are not at increased risk for the disease. For adults aed 65 and older, the decision to receive the CO 19 vaccine should also be based on individual-based decisionmaking. Additionally, it is recommended that healthcare providers discuss the risks, benefits, and any relevant risk factors before administering the vaccine. Updated CO 19 vaccines are typically released in the fall to match the most recent virus variants circulating globally. This timing makes October an ideal month to get vaccinated as the updated formulations are designed to offer stronger protection against the dormant strains expected during the winter season. Vaccination remains the most effective tool in helping protect high-risisk individuals from CO 19 and its complications. CO 19 vaccination and administration is one of the preventive services included as part of the Medicare part B preventive services benefit. Our objective for today is to provide an overview of the clinical aspects for the Medicare preventive service of CO 19 vaccine and its administration. During today’s webinar, we will cover background information about CO 19, different types of CO 19 vaccines available for the 2025 2026 season, and Medicare PartB coverage criteria for CO 19 vaccine and administration. Let’s start with a few facts and statistics. As of January 2025, more than 777 million cases of COVID 19 and 7 million deaths have been reported worldwide since the start of the pandemic, including approximately 104 million cases and over 1.1 million deaths in the United States alone. While most people infected with the virus recover without special treatment, some individuals, particularly adults aed 65 and over and those with underlying medical conditions, are at a higher risk for developing severe illness. Although CO 19 is no longer classified as a global emergency, it continues to cause intermittent outbreaks. Rising cases and emerging varants highlight the need for continued awareness as the virus can still lead to serious illness or death at any age. CO 19 or coronavirus disease 19 is an infection caused by the virus called SARS Kovv2. This virus began spreading rapidly in late 2019 leading to the global CO9 pandemic. CO 19 is very contagious. It is spread through respiratory droplets infected with SARS Kovv2 virus. When an infected person coughs, sneezes, talks or breathes, these respiratory droplets are released and spread from one person to another. Individuals may be exposed to the virus by inhaling these droplets or by touching contaminated surfaces than touching their eyes, nose, or mouth. Over time, the virus can change and evolve, resulting in new strains or variants. This has led to different vaccines being developed over the years in order to keep up with and help protect against the changing variance of the COVID 19 virus. Several factors can increase a person’s risk of developing severe illness from CO 19. So, let’s go over some of these important risk factors. The first risk factor is age. Age is considered the most significant risk factor for developing severe illness related to COVID 19 infection. Individuals aed 65 and over are at a higher risk for this issue and this risk continues to increase as the person ages. The second risk factor is having underlying medical conditions at the time of the CO 19 infection. These conditions include, but are not limited to, asthma, cancer, cerebrovascular disease, chronic kidney, lung or liver disease, cystic fibrosis, dementia, diabetes, heart disease, hematologic blood disorders, certain me mental conditions such as depression or schizophrenia and obesity. Having a disability such as cerebopal policy, Down syndrome or intellectual or developmental disabilities may place a person at a higher risk for developing severe illness due to contracting COVID 19. This risk may be attributed to both the person’s underlying medical conditions as well as social factors such as access to healthcare. The next risk factor is being imuninompromised due to an underlying medical condition or use of imunosuppressive medications or treatments. This includes individuals with weakened immune systems due to medical conditions such as HIV and AIDS, cancer treatments such as chemotherapy, organ transplantation requiring imunosuppressive medications or other imosuppressive therapies. A compromised immune system makes it harder to fight infections including CO 19 leading to more illness and more severe illness. The fifth risk factor is living or working in a high-risisk setting. For example, people who live in long-term care facilities like nursing homes or assisted living centers are at a higher risk. This is because these places often have many people living close together, which makes it easier for the virus to spread quickly. Also, residents in these facilities are often older or have underlying health conditions which can increase their chances of developing severe illness if they get CO 19. Similarly, staff members who work in these environments are at an increased risk due to frequent contact with close vulnerable individuals. The last risk factor we will mention is smoking. Smoking damages the lungs and impairs the immune response, increases susceptibility to severe respiratory infections like CO 19. In some cases, individuals infected with COVID 19 may experience either mild symptoms or no symptoms at all. However, certain individuals, particularly those with risk factors mentioned earlier, are more likely to develop severe illness from the virus. When symptoms do occur, they typically appear within 2 to 14 days after exposure and can last anywhere from 1 to 14 days. Common symptoms of CO 19 include fever, chills, fatigue, headache, muscle aches, sore throat, congestion or runny nose, shortness of breath or dispa, dry cough, loss of sense of smell, loss of sense of taste, and nausea, voming, or diarrhea. If the person is experiencing any of the following symptoms, they should seek immediate medical treatment. Difficulty breathing, cold, clammy skin, sinus of the skin, lips, or nail beds, persistent chest pain or pressure, drowsiness or loss of conscious consciousness, new onset of confusion or loss of speech or movement. Complications of severe COVID 19 infection include respiratory failure, sepsis, multiorgan failure and thrombbo embolism. A condition called multim inflammatory syndrome can occur several weeks after a co 19 infection. In children under the age of 20 21, this condition is known as multim inflammatory syndrome in children or MISC. While in adults aged 21 and older, it’s called multim inflammatory syndrome in adults or MISA. This rare condition is characterized by inflammation affecting multiple organ systems in the body including the heart, lungs, kidneys, brain, skin, eyes, and gastrointestinal tract. MIS is less common in adults than in children, making MISA a rare occurrence compared to MISC. Although many people fully recover from CO 19, some including those with mild cases may go on to develop a condition known as postcoid syndrome or postcoid9 syndrome. You may also hear it called longcoid long haul coid9 postcoid conditions or PCC or postacute squeli of SARS Kovv2 infection or pasque. For the purpose of this presentation, we will refer to it as postcoid9 syndrome. Postcoid9 syndrome includes a variety of new, recurring or persistent symptoms that appear more than four weeks after a covid-19 infection. People who experienced a severe cases case of CO 19 had certain pre-existing health conditions prior to contracting COVID 19 or developed multi symptom inflammatory syndrome during or after their infection or at a greater risk of developing postcoid9 syndrome. Symptoms of postcoid9 syndrome include but are not limited to general symptoms such as fever, symptoms that may get worse after physical or mental effort or post exertional malaise and changes in the length of menstrual cycle. Cardio respiratory symptoms including difficulty breathing or shortness of breath, cough, chest pain and heart palpitations. Circulatory symptoms such as blood clots and vascular issues including potential for pulmonary embolism. Gastrointestinal symptoms including diarrhea and stomach pain. Integmentaryary symptoms including rash. Muscularkeeletal symptoms such as joint or muscle pain. And neurological symptoms including fatigue, headache, difficulty thinking or concentrating. Dizziness when standing or lightadedness, tingling sensation or pins and needle feeling, sleep issues, loss of sense of smell, loss of sense of taste, and depression or anxiety. And these symptoms can last anywhere from several weeks to several years. Diagnosis of possible CO 19 infection typically begins with a physical examination by a healthcare provider. During this exam, the doctor will evaluate the patients symptoms such as fever, cough, fatigue, or difficulty breathing, which are common signs of co common signs of co 19. This initial assessment helps guide the next steps in the diagnostic process and provides insight into whether further testing is needed. While the physical exam provides important clues, testing is the most reliable and conclusive method for diagnosing CO 19. The most commonly used tests are antigen tests which offer faster results but they may be less accurate particularly in asymptomatic individuals. These tests detect the presence of SARS Kovv2 virus and confirm whether a person is currently infected. For individuals displaying symptoms of CO 19 it’s important to test as soon as possible. Rapid testing allows for early detection of the virus, helping healthcare providers to quickly advise on isolation, treatment options, and steps to prevent further transmission. Testing symptomatic individuals promptly also helps p officials track and manage the spread of the virus in communities. If a person has been exposed to CO 19 but is not showing symptoms, it is generally recommended to wait at least 5 days after exposure before getting tested. This waiting period is important because it allows the virus time to potentially replicate to detectable levels in the body. Testing too early, such as when the first within the first few days of exposure, may lead to a false negative result because the viral load might not might be too low to be detected. After 5 days, the likelihood of detecting the virus if the person is infected is higher, making a more reliable window for testing. According to the CDC, the PCR test provides the most accurate and reliable negative test result. If the patient is tested with the antigen test, it is generally more accurate at detecting a positive result, particularly in people with high viral loads or those who are symptomatic. However, it may not always provide an accurate negative result, especially in individuals with low viral loads, those who are asymptomatic, or those in the early stages of infection. Antigen tests are more prone to false negatives. If the antigen test shows a negative result, it is recommended the patient either complete another antigen test after 48 hours or obtain a PCR test as soon as possible for confirmation. If the second antigen test continues to report a negative result for the asymptomatic patient, it is recommended that the patient wait another 48 hours and repeat the antigen test for a third time. The FDA recommends two negative antigen tests for individuals who display symptoms and three negative antigen tests for those who are asymptomatic to confirm a negative finding. Per CMS’s COVID 19 over-the-counter tests, laboratory conducted COVID 19 tests are still covered for Medicare PartB beneficiaries when ordered by a healthcare provider. There’s no co-ayment, co- insurance, or deductible for the laboratory conducted CO 19 tests. However, Medicare no longer provides coverage or reimbursement for over-the-counter COVID 19 tests for Medicare PartB beneficiaries. And you can find a link to CMS’s CO9 over-the-counter tests on the resources slide at the end of the presentation. The CDC has issued guidance regarding isolation following the CO 19 diagnosis. They recommend individuals diagnosed with COVID 19 infection remain at home and avoid contact with others until at least 24 hours have passed since their symptoms began improving overall and they no longer have a fever and are no longer taking medication to reduce a fever. However, please note that these isolation guidelines may be updated as new information becomes available or when deemed necessary. It is also advised that the person take additional precautions for 5 days after the isolation period ends. These precautions include wearing a well-fitting mask, maintaining distance from others, avoiding public places if unable to wear a mask, opting for outdoor or well ventilated indoor gatherings, practicing good hand hygiene and overall hygiene practices, and getting tested before meeting with others when possible. If symptoms or a fever return, the individual should resume precautions by staying home and avoiding contact with others until symptoms have improved and they’ve remained fever-free for at least 24 hours. Most individuals are able to recover at home by getting adequate rest and staying well hydrated. Additionally, symptoms can be managed with overthe-counter remedies such as acetaminophen or ibuprofen for fever and muscle aches and cough drops or throat sprays as needed for sore throat and cough. For those at a higher risk for severe illness, such as older adults and individuals with weakened immune systems, antiviral medications may be prescribed to help reduce the risk of serious complications or death. These treatments are most effective when taken within 5 days of the onset of symptoms. There are several measures individuals can take to help reduce the chances of contracting CO 19. The first measure is getting vaccinated against CO 19. While the vaccine may not completely eliminate the risk of contracting the virus, it significantly lowers the risk of severe illness, hospitalization, and death for those who get vaccinated. Next is practicing good hygiene and health habits such as washing hands frequently with soap and water or using an alcohol-based sanitizer if soap and water are not available. Covering nose and mouth when coughing or sneezing by using the inside of the elbow or using a tissue. And make sure to promptly dispose of the used tissue and wash hands following coughing and sneezing. regularly cleaning and disinfecting high contact areas such as doorork knobs, light switches, and countertops and avoiding large crowds and keeping a safe distance from others. Wearing a mask in a crowded setting can help, especially indoors. And when the options available, choose activities where there is more fresh air circulation, such as activities outside versus in a crowded room. The last measure we will mention we will mention is getting tested for CO 19. If having symptoms consistent with COVID 19 infection, if a person has tested positive for CO 19 or is already symptomatic, advise them to take the following precautions. Follow the CDC isolation precautions by staying home and avoiding contact with others until at least 24 hours after symptoms have improved, there is no fever, and no fever reducing medication is being taken. This also includes taking additional precautions for 5 days after the isolation period ends. Additionally, individuals at higher risk for severe COVID 19 infection should seek medical care from their healthcare provider. Before we continue, let’s take a moment to briefly discuss the mental health aspects for those diagnosed with CO 19 infection. For some individuals, a CO 19 diagnosis can lead to increased stress which may result in symptoms like insomnia, anxiety, or depression. In certain cases, these mental health challenges may trigger unhealthy coping mechanisms such as substance abuse or thoughts of suicide. It’s important for healthcare providers to assess patients for any mental health concerns or harmful behaviors and develop a strategy to support them through these challenges. This support can include depression screenings, counseling, and referral to community resources such as the 988 suicide and crisis lifeline. While we won’t go into detail on these services in today’s session, we do have encore presentations available to delve delve deeper into the topic of mental health. A link to the mental health playlist on our YouTube channel is available on the resources slide at the end of this presentation. One of the best ways to reduce the risk of contracting CO 19 and its associated complications is by receiving the CO 19 vaccine. The FDA has instructed manufacturers of approved vaccines to develop monalent formulations based on the JN1 lineage prioritizing the LP81 strain for the fall 2025 respiratory season in the US. This recommendation followed the May 22nd meeting of the vaccines and related biological products advisory committee which reviewed data from Madna, Fizer, Biantech and Novivvax, Seni. The committee unanimously recommended targeting the JN1 lineage to better align with circulating SARS KV2 strains and to ensure the new formulations effectively match the evolving virus particularly focusing on the LP81 strain. The FDA has approved the following updated CO 19 vaccines for the 2025 2026 season to help protect against severe complications from COVID 19. Fiser Biionechity vaccine, Madna spike vax vaccine, Mona’s Nex spike vaccine, and Novivvax Newaxivid COVID 19 vaccine. Let’s now examine each of the newly approved COVID 19 vaccines for the 2025 2026 season in greater detail to gain a clearer understanding of how they work. The Fiser, Biionech and Madna vaccines are mRNA vaccines. They use messenger RNA to deliver genetic instructions to the body cells. The mRNA instructs the cells to produce the spike protein found on the surface of the SARS Kovv2 virus. Once the spike protein is made, the immune system recognizes it as foreign and builds a defense, preparing the body to respond if exposed to the actual virus in the future. These vaccines serve as a guide prompting the immune system to recognize and respond to the virus. Both the Fiser Biotech community and the Madna spike vaccines contain the whole spike protein. Maderna’s latest formulation M next spike is a bvevalent vaccine developed to improve protection against both the original strain of the SARS KV2 and newer variants of the virus. It uses messenger RNA to encode a modified version of the entire spoke spike protein including key segments such as the receptor binding domain and the end terminal domain to better target the varants. This updated vaccine uses a lower dose about 1/5if the amount found in the original spike while maintain strong immune responses capabilities. The novivvax vacid vaccine is a protein subunit vaccine which works differently from mRNA vaccines. It contains a recominant spike protein along with a matrix M adguant which helps boost the body’s immune response. Unlike mRNA vaccines that instruct the body’s cells to produce the spike protein, vacaxivid delivers the spike protein directly. This allows the immune system to recognize the spike protein immediately while the matrix M agitant helps stimulate a stronger and more effective immune reaction. Now that we reviewed how each vaccine works, let’s go over the indications and recommended dosages for each. First we have Fiser Biantex community. This vaccine is approved for adults aged 65 and older as well as those for for individuals aged 5 years to 64 years of age who have at least one underlying medical condition that increases the risk for severe COVID 19. It is administered as a single 0.1 milll dose. For those who have already received any CO 19 vaccine, community should be given at least two months after their last dose. Next is Madna Spike Vax. Spike Vax is approved for adults aged 65 and older as well as for individuals aged 6 months to 64 years of age who have at least one underlying medical condition that increases their risk for severe COVID 19. It is administered as a single 0.5 milll dose for individuals aed 12 years old and older and as a single 0.25ml dose for those aged 6 months through 11 years. Doing for children under two years of age depends on the number of prior madna vaccine doses received. For previously vaccinated individuals aged 2 years and older, spike vac should be given at least two months after their last co 19 vaccine dose. The third vaccine is Madna’s M next spike. This vaccine is approved for adults aed 65 and older as well as for individuals aged 24 to 64, oh sorry, age 12 to 64 who have at least one underlying medical condition that increases their risk for severe COVID 19. It is given as a single 0.2 milll dose administered at least three months after their last COVID 19 vaccine dose. Lastly, we have Novivvax Nvacivid. It is approved for adults aed 65 and older as well as for individuals aged 12 to 64 who have at least one underlying medical condition that increases the risk for severe COVID 19. Nvacivid is administered as a single 0.5 milliliter dose. For those previously vaccinated, it should be given at least two months after their last COVID 19 vaccine dose. And all four vaccines are administered via intramuscular injection in the deltoid muscle. Possible side effects of CO 19 vaccine may include soreness, redness, tenderness or swelling at the site of injection, headache, muscle aches, joint pain, fever, chills, nausea and vomiting, fatigue, and in rare cases, fainting shortly after the injection. A severe allergic reaction such as hives, widespread rash, swelling of the face, throat, and airway. Problems breathing, wheezing or low blood pressure can occur. Immediate emergency treatment is necessary if the patient shows any signs of severe allergic reaction and healthcare providers should report any adverse reactions to the vaccine adverse event reporting system or veyors. Medicare covers CO 19 vaccine and administration for all patients with Medicare Part B. CMS recommends providers review the FDA emergency use authorization criteria for the frequency of each CO 19 vaccine. There’s no co-ayment, co insurance, or deductible as long as the healthcare provider accepts assignment. The Medicare reimbursement rate for administering the CO 19 vaccine differs from the rate for administering other preventive vaccines under part B such as those for flu, hepatitis B, and numaccoal diseases. And you can find additional information about payment, billing, and coding for CO 19 vaccines on CMS’s COVID 19 vaccine toolkit. And a link to this resource has been placed at the bottom of this slide. Now, let’s review some additional information regarding coverage for CO 19 vaccines. The Centers for Medicare and Medicaid Services will reimburse 100% of the reasonable cost for CO 19 vaccines and their administration in rural health clinics and federally qualified health centers. This payment is separate from the standard FQC perspective payment system or RAC all-inclusive rate. This change aims to simplify the payment process for all part B vaccines in these settings. Additionally, beginning July 1st, 2025, RHC’s and FQC’s will be able to bill for all four types of part B preventive vaccines, including the CO 19 vaccine and its administration at the time of service, regardless of whether a qualifying visit occurs. Medicare provides an additional payment for administering CO 19 vaccines in certain patients homes. This includes patients who are unable to leave their homes due to a medical condition that limits their ability to leave the home without assistance, being more prone to contracting a disease if they left their homes, requiring considerable and taxing effort to leave the home. having a disability or having a clinical, socioeconomic, or geographic barrier to receiving the vaccination outside their homes. Examples of the Medicare patients home include a private residence, temporary lodging, for example, a hotel or motel, campground, hostel, or homeless shelter, an apartment in an apartment complex, or unit in assisted living facility, group home, or non-medaid nursing facility, and a Medicare patients home that’s been made provider-based to a hospital during the CO 19 public health emergency. As of August 24th, 2021, the following two locations are also considered the Medicare’s patient, the Medicare patients home, communal spaces in a multi-unit or communal living arrangement, and assisted living facilities participating in the CDC’s pharmacy partnership for long-term care program where the resident vaccinations are provided through this program. The following locations do not qualify as a home for the additional payment amount. Communal spaces of a multi-living or communal arrangement prior to August 24th, 2021. Hospitals except when the Medicare patients home was made provider-based to the hospital during the CO 19 public health emergency and Medicare skilled nursing facilities and Medicaid nursing facilities regardless of whether they are the patients permanent residents. Certification of homebound status is not a requirement for the patient to receive the CO 19 vaccination in their homes. However, the healthcare provider should clearly document the patient’s specific reason or barriers that prevent them from receiving vaccinations outside the home. Medicare provides the additional inhome payment only when the sole purpose of the visit is to administer one or more part B preventive vaccines. If another Medicare coverage service is delivered in the same home on the same day, the additional inhome payment will not be made. In such cases, only the standard vaccine administration fee applies. For calendar year 2025, Medicare pays approximately $45 for inhome administration of the CO 19 vaccine and an additional inhome payment of approximately $40. These payments are geographically adjusted based on the location of the service and are updated annually to reflect changes in vaccination administration costs. When CO 19 vaccines are administered to more than one Medicare patient in the same home or community living setting on the same day, Medicare will pay the standard administration fee for each vaccine given. However, the additional in-home payment is made only once per patient per day of service regardless of the number of part B preventive vaccines administered. Additionally, Medicare will pay the additional inhome fee for up to five vaccine administrations per group living location per day, but only if fewer than 10 Medicare beneficiaries receive a vaccine there on the same day. If 10 or more beneficiaries are vaccinated at the same group living location on the same day, the additional inhome payment is limited to one home or communal space. And for further details, please refer to CMS’s Medicare CO9 vaccine shot payment and a link to this can be found on the resources slide at the end of the presentation. Documentation requirements for CO 19 vaccine and administration include date service was provided and details regarding the administration of the vaccine including the manufacturer and lot number, site the vaccination was administered, dosage route and name and credentials of the person administering the vaccination. According to CMS’s Medicare billing for CO 19 vaccine shot administration, a physician’s order is not required for the CO 19 vaccine and it can be administered without physician supervision and this applies to the initial doses, additional doses, and booster doses of the CO 19 vaccine. Ensure all documentation is dated and signed with the provider’s credentials. Vaccination against CO 19 may help reduce the risk of infection and lessen the severity of related health issues, especially for those at high risk for severe outcomes. So, as a recap, during today’s webinar, we provided background information about CO 19, including symptoms, testing, and treatment, reviewed the different types of CO 19 vaccines available for the 2025 2026 season, and discuss the Medicare part B coverage criteria for CO 19 vaccine and administration. This slide contains links to resources related to information covered in today’s presentation. The first link is to the US Department of Health and Human Services press release on September 19th, 2025 related to the ACIP recommendations for COVID 19 immunizations. The next links include materials from the Centers of Medicare and Medicaid Services such as the MLN00006559 Medicare preventive services chart, the Medicare COVID 19 vaccine shot payment web page, and the CO9 over-the-counter tests web page. The final links directly direct you to the mental health and encore presentation playlist on our YouTube channel. We encourage you to explore the videos on these playlists for additional education on a variety of relevant topics and please refer to this slide as a helpful reference when reviewing the presentation materials. We are now at the end of the formal presentation. Please remember if you have any questions, please put those questions in the chat. If we don’t get to your questions today during the presentation, we will send out a document to all participants with the answers following this webinar. So, I’m going to take a look at the chat and I do not currently see any questions, but again, if you do have a question, just place it in the chat and I’ll take a look before we end and uh answer that question if we do have any in there. For those attending today’s live event, in a few minutes, you will receive an email thanking you for attending. And the email looks like what you’ll see here on the left side of your screen. Do not delete it without reading it. This email contains your certificate of achievement as well as a link to take the survey. And if you haven’t completed it already, please take a few moments to complete the customer satisfaction survey. The contact hours for this event can be found in this email should you require them for earning credit to a continuing education units. If you don’t see it, please check your junk or spam folder. Make sure to add the WebEx email address [email protected] to your safe sender safe receiver list to avoid these emails going to junk or spam. And if you called into this webinar, just email us at wps.gha.educationwpsic.com with the name of this webinar and the phone number you use to log in and we can email you your certificate of achievement. Following today’s live event, if you think of any additional questions, you have seven days from today to submit them. Submit them to our education mailbox at wps.gha.education at wpsic.com and put coid9 vaccine and administration in the subject line. If you just put co 19 in there, we will receive it. And here is that email address. And we did put the uh subject line in there. So if you click on this, you can get right to that email address with the subject line. However, if you do have claim specific questions, please do not send those to provider outreach and education. Please direct those questions to our customer service department as we do not have access to your claim information and therefore unable to look up claims. Also, remember we cannot accept any type of PHI or PII via email. If you haven’t done so already, please take a few minutes now to complete a survey. Share with CMS and us about your experience today. Tell us about your experience, including what you liked, what we could do to improve, and suggestions for future education. Your feedback is really invaluable in helping us deliver the education you need. We use your feedback to develop topics for future education events. And there are several options you can use to take the survey depending on your preference. For those attending today’s live event, the first option is to click the survey in the chat. The other option is take the survey on the CMS Qualrex page. So when you exit the webinar, you’ll be asked to go to an external site and that external site is the CMS Qualrix page for the survey. And the message looks sort of like what you see here with that little yellow triangle. That site is not spam. It’s actually directing you straight to our survey. And we’ll also add the survey link to the Encore presentation. Just click on the survey picture at the end of the encore presentation video to take our customer satisfaction survey. Based on your feedback, we’ve added several enhanced features to improve your educational experience. Our encore presentation videos now include chapters making it easier for you to find key information quickly. We’ve also induced introduced training indicators during our webinar registration to help identify the attended audience for each session. So, for this one, we had CLI N, uh, Part B. Um, if it’s a billing one, you might see Bill, um, new to Medicare. So, that really will help you decide what webinars really do apply to your practice. And we’re hoping these enhancements make your learning experience even more valuable and accessible. And I’m just going to quickly look at the chat one more time. And I do not see any questions, so we’ll move on to the ending. So on behalf of Tom, myself, and all the provider outreach and education, thank you for attending today’s webinar on CO 19 vaccine and administration. As a reminder, this presentation will be posted as an encore presentation on the training center page on our website. Remember to take our survey with the link provided. We look forward to your survey comments and hope to have you join us at future events. You may now disconnect.
